| Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies |
caitiestaat |
Nov 30, 2015 9:43:01 PM |
| Guidance for Industry: Expedited Programs for Serious Conditions - Drugs and Biologics |
caitiestaat |
Nov 30, 2015 9:39:39 PM |
| Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies |
caitiestaat |
Nov 30, 2015 9:38:28 PM |
| Food and Drug Administration Safety and Innovation Act (FDASIA) - Frequently Asked Questions: Breakthrough Therapies |
caitiestaat |
Nov 30, 2015 9:36:23 PM |
| Orphan Drug Act |
caitiestaat |
Nov 30, 2015 9:22:36 PM |
| OpportunityAnalyzer: Duchenne Muscular Dystrophy – Opportunity and Market Analysis to 2019 |
aborenstein15 |
Nov 30, 2015 9:03:07 PM |
| National Vital Statistic Reports-Births: Final Data for 2013 |
aborenstein15 |
Nov 30, 2015 9:02:37 PM |
| Exon skipping therapy for Duchenne muscular dystrophy |
Mandar Makwana |
Nov 29, 2015 8:39:32 AM |
| Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy |
aborenstein15 |
Nov 29, 2015 6:39:30 AM |
| Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations |
aborenstein15 |
Nov 29, 2015 6:35:13 AM |
